JP2016512527A - 動脈瘤性くも膜下出血の合併症を治療するための組成物およびそれらの使用 - Google Patents

動脈瘤性くも膜下出血の合併症を治療するための組成物およびそれらの使用 Download PDF

Info

Publication number
JP2016512527A
JP2016512527A JP2016501330A JP2016501330A JP2016512527A JP 2016512527 A JP2016512527 A JP 2016512527A JP 2016501330 A JP2016501330 A JP 2016501330A JP 2016501330 A JP2016501330 A JP 2016501330A JP 2016512527 A JP2016512527 A JP 2016512527A
Authority
JP
Japan
Prior art keywords
therapeutic agent
cerebral
use according
artery
sah
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016501330A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512527A5 (https=
Inventor
ロッホ アール マクドナルド
ロッホ アール マクドナルド
Original Assignee
エッジ セラピューティクス インコーポレイテッド
エッジ セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エッジ セラピューティクス インコーポレイテッド, エッジ セラピューティクス インコーポレイテッド filed Critical エッジ セラピューティクス インコーポレイテッド
Publication of JP2016512527A publication Critical patent/JP2016512527A/ja
Publication of JP2016512527A5 publication Critical patent/JP2016512527A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016501330A 2013-03-11 2014-03-11 動脈瘤性くも膜下出血の合併症を治療するための組成物およびそれらの使用 Pending JP2016512527A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/793,767 2013-03-11
US13/793,767 US10092524B2 (en) 2008-06-11 2013-03-11 Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
PCT/US2014/023748 WO2014164904A1 (en) 2013-03-11 2014-03-11 Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage

Publications (2)

Publication Number Publication Date
JP2016512527A true JP2016512527A (ja) 2016-04-28
JP2016512527A5 JP2016512527A5 (https=) 2017-02-16

Family

ID=49157870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501330A Pending JP2016512527A (ja) 2013-03-11 2014-03-11 動脈瘤性くも膜下出血の合併症を治療するための組成物およびそれらの使用

Country Status (14)

Country Link
US (2) US10092524B2 (https=)
EP (1) EP2968166A4 (https=)
JP (1) JP2016512527A (https=)
KR (1) KR101902319B1 (https=)
CN (1) CN105324108A (https=)
AU (1) AU2014248877A1 (https=)
BR (1) BR112015022218A2 (https=)
CA (1) CA2905327A1 (https=)
GB (1) GB2528801A (https=)
HK (1) HK1216002A1 (https=)
NZ (1) NZ629730A (https=)
RU (1) RU2015143206A (https=)
SG (1) SG11201507398XA (https=)
WO (1) WO2014164904A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
RU2606169C2 (ru) 2011-04-05 2017-01-10 Эдж Терапьютикс Система интравентрикулярной доставки лекарственного средства для улучшения исхода после повреждения головного мозга, нарушающего мозговое кровообращение
CN107921036A (zh) * 2015-05-29 2018-04-17 优势医疗公司 用于减少视力丧失的组合物和方法
US20190054022A1 (en) * 2016-04-07 2019-02-21 Edge Therapeutics, Inc. Formulations of site-specific, microparticulate compositions and their use to improve outcome after aneursymal subarachnoid hemorrhage
CN108403629B (zh) * 2018-04-26 2019-11-05 徐州医科大学 一种尼莫地平口服长效悬浮液及其制备方法
EP3965635A4 (en) * 2019-05-07 2023-05-31 Yale University MAXIMIZING THE DISTRIBUTION AND MINIMIZING THE WASHOUT OF INJECTION SOLUTIONS IN BONE AND METHODS FOR IMPROVED EXTRACTION OF ASPIRATE
KR102425548B1 (ko) * 2019-05-22 2022-07-26 경북대학교 산학협력단 Cacb1 유래 펩타이드, Cacb1 유래 펩타이드의 변이체 및 이의 용도
WO2021168351A1 (en) * 2020-02-20 2021-08-26 Postsurgical Therapeutics, Inc. Brain drug delivery system and method
WO2021262725A1 (en) * 2020-06-22 2021-12-30 Curelator, Inc. Systems and methods for segmentation of a user population based on time-based variations in biomarker levels
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN116997370A (zh) * 2021-03-03 2023-11-03 克朗医疗有限公司 作为临时栓塞剂的藻酸盐基颗粒
WO2025151741A1 (en) * 2024-01-10 2025-07-17 Brown David Donaldson Methods of treating migraine headache or tension headache with hyaluronic acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109664A1 (en) * 2011-02-11 2012-08-16 Edge Therapeutics Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
WO2012138854A1 (en) * 2011-04-05 2012-10-11 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757128A (en) 1986-08-01 1988-07-12 Massachusetts Institute Of Technology High molecular weight polyanhydride and preparation thereof
US4937270A (en) 1987-09-18 1990-06-26 Genzyme Corporation Water insoluble derivatives of hyaluronic acid
US5527893A (en) 1987-09-18 1996-06-18 Genzyme Corporation Water insoluble derivatives of polyanionic polysaccharides
DK0471036T4 (da) 1989-05-04 2004-07-19 Southern Res Inst Indkapslingsfremgangsmåde
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5399665A (en) 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
AU704183B2 (en) 1994-01-05 1999-04-15 Arqule, Inc. Systematic modular production of aminimide- and oxazolone-based molecules having selected properties
US5712171A (en) 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
AT404429B (de) 1995-06-09 1998-11-25 Immuno Ag Anti-plasma-antikörper-präparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
CN1304058C (zh) 1996-03-12 2007-03-14 Pg－Txl有限公司 水溶性紫杉醇产品
JP4642946B2 (ja) 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
US6123956A (en) * 1997-07-10 2000-09-26 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6358536B1 (en) 1997-10-15 2002-03-19 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
JP2000070366A (ja) 1998-09-02 2000-03-07 Arute:Kk 容器兼用注射器及び容器兼用注射器への凍結乾燥製剤の封入方法
US20050214227A1 (en) * 1999-03-08 2005-09-29 Powderject Research Limited Microparticle formulations for sustained-release of bioactive compounds
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
US6284283B1 (en) 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
CA2396016A1 (en) 1999-12-29 2001-07-05 Andy Bernhardt System for reconstituting pastes and methods of using same
JP2003520830A (ja) 2000-01-25 2003-07-08 エドワーズ ライフサイエンシーズ コーポレイション 再狭窄および吻合内膜過形成処置のための送達系
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002003406A (ja) 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
US20030032676A1 (en) 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
WO2003020208A2 (en) 2001-08-31 2003-03-13 Neuron Therapeutics, Inc. Treatment of neurologic hemorrhage
US20040235801A1 (en) 2001-10-25 2004-11-25 Jean-Pierre Julien Therapy for stroke
DE60236686D1 (de) 2001-11-22 2010-07-22 Dainippon Sumitomo Pharma Co Nichtmenschliches tiermodell, das nicht auf eine immunopotenzierende synthetische verbindung anspricht
DE60335608D1 (de) 2002-02-27 2011-02-17 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
TW200307011A (en) 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
WO2003093465A1 (en) 2002-04-30 2003-11-13 Maxygen Holdings Ltd. FACTOR VII OR VIIa POLYPEPTIDE VARIANTS
RU2005102604A (ru) 2002-07-03 2005-09-10 Перикор Сайенс, Инк. (Us) Композиция гиалуроновой кислоты и способы применения
ATE487470T1 (de) 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
JP4092994B2 (ja) 2002-09-13 2008-05-28 ニプロ株式会社 プレフィルドシリンジキット
EP1575562B1 (en) * 2002-11-26 2016-10-05 Seacoast Neurosciene, Inc. Buoyant polymer particles delivering therapeutic agents
ES2427092T3 (es) 2003-04-10 2013-10-28 Evonik Corporation Un método para la producción de micropartículas a base de emulsión
US20070207211A1 (en) 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
JP5165240B2 (ja) 2003-07-23 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 徐放組成物
US9149440B2 (en) * 2003-09-02 2015-10-06 University Of South Florida Nanoparticles for drug-delivery
WO2005042048A2 (en) 2003-10-22 2005-05-12 Encelle, Inc. Bioactive hydrogel compositions for regenerating connective tissue
WO2006002365A2 (en) 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US8034762B2 (en) 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
WO2006084005A2 (en) 2005-02-02 2006-08-10 University Of Vermont And State Agricultural College Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
EP1858542A4 (en) 2005-02-24 2009-08-19 Joslin Diabetes Center Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VASPEREPERMABILITY
US20060217340A1 (en) 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity
WO2006114105A2 (en) 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
US20090156481A1 (en) 2005-07-15 2009-06-18 Novo Nordisk Healthcare A/G Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy
GB0515492D0 (en) 2005-07-28 2005-08-31 Reckitt Benckiser Healthcare Improvements in or relating to compositions,articles and methods
CA2625862A1 (en) 2005-10-14 2007-04-26 Transform Pharmaceuticals, Inc. Liquid pharmaceutical compositions of nimodipine
EP1951262A4 (en) 2005-11-21 2010-09-15 Univ Alabama METHOD OF USING SMALL-MOLECOLLAR COMPOUNDS FOR NERVE PROTECTION
US8980817B2 (en) 2007-01-18 2015-03-17 Reckitt Benckiser N.V. Dosage element and a method of manufacturing a dosage element
US20100185219A1 (en) 2007-04-25 2010-07-22 Musculosketetal Transplant Foundation Reinforced biological mesh for surgical reinforcement
US9005183B2 (en) 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
WO2008154585A1 (en) 2007-06-11 2008-12-18 Macdonald R Loch A drug delivery system for the prevention of cerebral vasospasm
WO2009085952A1 (en) 2007-12-20 2009-07-09 Brookwood Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
US20100008968A1 (en) 2008-06-26 2010-01-14 Lampe John W Method for treating cardiovascular diseases using rho kinase inhibitor compounds
EP2328549B1 (en) 2008-08-22 2017-11-15 Reckitt Benckiser Healthcare (UK) Limited Sore throat compositions
WO2010030868A1 (en) 2008-09-11 2010-03-18 Surmodics Pharmaceuticals, Inc. Solvent extraction microencapsulation with tunable extraction rates
JP5769626B2 (ja) 2008-09-18 2015-08-26 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 溶媒および塩を用いるマイクロカプセル封入プロセス
CA2750003A1 (en) 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Controlled release systems from polymer blends
US20130059008A1 (en) 2009-01-23 2013-03-07 Jeffrey L. Atkinson Drying methods for tuning microparticle properties
WO2010085608A1 (en) 2009-01-23 2010-07-29 Surmodics Pharmaceuticals, Inc. Polymer mixtures comprising polymers having different non-repeating units and methods for making and using same
US20100291027A1 (en) 2009-05-14 2010-11-18 Jason Campbell Hyaluronic acid (ha) injection vehicle
US20110033463A1 (en) 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
CA2784287C (en) 2009-12-22 2017-07-18 Evonik Degussa Corporation Emulsion-based process for preparing microparticles and workhead assembly for use with same
EP2538956A4 (en) 2010-02-22 2015-04-22 Edge Therapeutics Inc METHODS AND COMPOSITIONS FOR TREATING HEMORRHAGIC BRAIN DISORDERS
CA2794328C (en) 2010-03-29 2018-01-16 Evonik Degussa Corporation Compositions and methods for improved retention of a pharmaceutical composition at a local administration site
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012109664A1 (en) * 2011-02-11 2012-08-16 Edge Therapeutics Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
WO2012138854A1 (en) * 2011-04-05 2012-10-11 Edge Therapeutics Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow

Also Published As

Publication number Publication date
RU2015143206A (ru) 2017-04-18
EP2968166A1 (en) 2016-01-20
HK1216002A1 (zh) 2016-10-07
CA2905327A1 (en) 2014-10-09
AU2014248877A1 (en) 2015-10-01
NZ629730A (en) 2017-03-31
US20130243864A1 (en) 2013-09-19
GB201516997D0 (en) 2015-11-11
KR101902319B1 (ko) 2018-09-28
US20160324796A1 (en) 2016-11-10
KR20150136084A (ko) 2015-12-04
BR112015022218A2 (pt) 2017-07-18
EP2968166A4 (en) 2016-10-05
SG11201507398XA (en) 2015-10-29
GB2528801A (en) 2016-02-03
WO2014164904A1 (en) 2014-10-09
CN105324108A (zh) 2016-02-10
US10092524B2 (en) 2018-10-09
AU2014248877A8 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
KR101902319B1 (ko) 동맥류 지주막하 출혈의 합병증 치료를 위한 조성물 및 그의 용도
JP6336899B2 (ja) 脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム
KR101554250B1 (ko) 뇌혈관 연축의 예방을 위한 약물 전달 시스템
JP6146814B2 (ja) クモ膜下出血のヒトの予後を改善する組成物及び方法
US20190054022A1 (en) Formulations of site-specific, microparticulate compositions and their use to improve outcome after aneursymal subarachnoid hemorrhage
CA2826890A1 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
HK1230079A1 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
NZ613970B2 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
NZ727856B2 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170828

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190124